^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Zynlonta (loncastuximab tesirine-lpyl) (DNA replication inhibitor, CD19-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    ADC Therapeutics Press Release
    Published date:
    12/21/2022
    Excerpt:
    ADC Therapeutics SA...and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted conditional marketing authorization for the use of ZYNLONTA® (loncastuximab tesirine) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    04/23/2021
    Excerpt:
    ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Diffuse Large B cell Lymphoma...Third-line and subsequent therapy: Loncastuximab tesirine (only after ≥2 lines of systemic therapy) was added as a category 2A recommendation.